Literature DB >> 28032371

Tadalafil for male lower urinary tract symptoms improves endothelial function.

Kazuhiko Fukumoto1, Atsushi Nagai1, Ryoei Hara1, Tomohiro Fujii1, Yoshiyuki Miyaji1.   

Abstract

OBJECTIVES: To investigate the effects of tadalafil on vascular endothelial function and cardiovascular risk in patients with prostatic hyperplasia.
METHODS: Tadalafil 5 mg was given to 20 patients with prostatic hyperplasia for whom an α1-blocker was ineffective. Voiding symptoms and vascular endothelial function were investigated before and after 4 and 12 weeks of administration, using commercial tests for vascular function and vascular endothelial function.
RESULTS: The participants had a median age of 65 years, a mean body mass index of 24.2 and a mean prostate volume of 36.2 mL measured using transabdominal sonography. Voiding symptoms were significantly improved by tadalafil, based on the International Prostate Symptom Score, quality of life index and overactive bladder symptom score (P < 0.05). There were also significant improvements in vascular function (change of brachial-ankle pulse wave velocity from 1701 [before] to 1657 [4 weeks tadalafil] and 1525 [10 weeks tadalafil] cm/s [P < 0.05]) and vascular endothelial function (change of reactive hyperemia index from 1.36 to 1.56 and 1.89 [P < 0.05]). The change in reactive hyperemia index was significantly correlated with International Prostate Symptom Score, quality of life index and brachial-ankle pulse wave velocity.
CONCLUSIONS: The improvement in intrapelvic blood flow by tadalafil can result in improved vascular endothelial function, in addition to improvement of voiding symptoms. The change in reactive hyperemia index seems to correlate with the severity of voiding symptoms, with tadalafil being most effective in patients with mild voiding symptoms.
© 2016 The Japanese Urological Association.

Entities:  

Keywords:  blood flow; lower urinary tract symptoms; reactive hyperemia index; tadalafil; vascular endothelium

Mesh:

Substances:

Year:  2016        PMID: 28032371     DOI: 10.1111/iju.13273

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  5 in total

1.  Oxidative stress marker 8-hydroxyguanosine is more highly expressed in prostate cancer than in benign prostatic hyperplasia.

Authors:  Shinji Ohtake; Takashi Kawahara; Yukari Ishiguro; Teppei Takeshima; Shinnosuke Kuroda; Koji Izumi; Hiroshi Miyamoto; Hiroji Uemura
Journal:  Mol Clin Oncol       Date:  2018-07-03

2.  Is tadalafil associated with decreased risk of major adverse cardiac events or venous thromboembolism in men with lower urinary tract symptoms?

Authors:  Sankalp Goberdhan; Ruben Blachman-Braun; Sirpi Nackeeran; Thomas A Masterson; Ranjith Ramasamy
Journal:  World J Urol       Date:  2022-04-25       Impact factor: 3.661

3.  Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.

Authors:  Smita Pattanaik; Ravimohan S Mavuduru; Arabind Panda; Joseph L Mathew; Mayank M Agarwal; Eu Chang Hwang; Jennifer A Lyon; Shrawan K Singh; Arup K Mandal
Journal:  Cochrane Database Syst Rev       Date:  2018-11-16

4.  Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia.

Authors:  Tomoaki Tanaka; Akinori Minami; Kouichiro Tashiro; Naomasa Yoshida; Akira Tohda; Yasuo Yamakoshi; Ryoji Yasumoto; Shozo Sugita; Tatsuya Nakatani
Journal:  Future Sci OA       Date:  2018-03-15

5.  The impact of smoking on male lower urinary tract symptoms (LUTS).

Authors:  Takashi Kawahara; Hiroki Ito; Hiroji Uemura
Journal:  Sci Rep       Date:  2020-11-19       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.